Pharma major Wockhardt today said it has received approval from the US drug regulator for marketing its anti-epileptic tablet Levetiracentam in that country.
The company has received approval from the United States Food & Drug Administration (USFDA) for marketing of Levetiracentam tablets in the strength of 250, 500, 750 mg and 1 gm, Wockhardt said in a filing to the Bombay Stock Exchange.
Levetiracentam tablets are used in the treatment of various kinds of epileptic seizures.
"With nearly 60 products now in the market, we are continuing to strengthen our US business by filing several abbreviated new drug approvals all indigenously developed by the company's research and development team," Wockhardt Chairman Habil Khorakiwala said.
On Wednesday, Wockhardt had said the company has received final approval from the USFDA for the marketing of Divalporex Extended Release (ER) tablets also used in the treatment of various kinds of epileptic seizures.